Screening for diminished ovarian reserve in Portugal: a cost-saving answer to shorten the fertility journey

AIM: Assess the budget impact of nationwide screening for diminished ovarian reserve (OR), via anti-Müllerian hormone (AMH) levels, to the Portugal National Health System (NHS). PATIENTS & METHODS: The clinical journey was determined using literature and the family planning decision-making proce...

Descripción completa

Detalles Bibliográficos
Autores principales: Xavier, Pedro, Dantas, Sofia, Almeida-Santos, Teresa, Soares, Sérgio Reis, Imhoff, Ryan J, Genovez, Victória, Modesto, Cátia, Gens, Helena, Correia, Inês, Catalão, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Becaris Publishing Ltd 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508297/
https://www.ncbi.nlm.nih.gov/pubmed/37345566
http://dx.doi.org/10.57264/cer-2023-0003
Descripción
Sumario:AIM: Assess the budget impact of nationwide screening for diminished ovarian reserve (OR), via anti-Müllerian hormone (AMH) levels, to the Portugal National Health System (NHS). PATIENTS & METHODS: The clinical journey was determined using literature and the family planning decision-making process/response using survey results. A panel of four local clinicians validated all assumptions/inputs. RESULTS: Screening for OR led to an expected savings of € 9.4 million for the NHS, driven by a 24% reduction in medically assisted reproduction (MAR) use. When needed, referral for MAR was earlier and more women used first-line versus second-line techniques. The model estimated a 12% decrease in failure. CONCLUSION: This model shows AMH screening may allow more informed decisions, leading to a shorter fertility journey, more efficient use of treatments, and substantial cost-savings for the NHS.

Ejemplares similares